Trapidil

Overview

Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor ( PDGF ) , inhibits phosphodiesterase , thromboxane A 2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.

Application

Products | Products > Disease Areas > Heart Disease | Products > Disease Areas > Nervous System Injury | Products > Disease Areas > Angina | Products > Disease Areas > Cardiomyopathy | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > Prostaglandin Receptor

Product Information

• Catalog No.: HY-B1016
• CAS No.: 15421-84-8
• Molecular Formula: C10H15N5
• Molecular Weight: 205.26
• Purity: 98.0%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 100 mg/mL (487.19 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source